OPKO Health (OPK)
Market Price (4/12/2026): $1.15 | Market Cap: $881.0 MilSector: Health Care | Industry: Life Sciences Tools & Services
OPKO Health (OPK)
Market Price (4/12/2026): $1.15Market Cap: $881.0 MilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Low stock price volatilityVol 12M is 37% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -87% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.91 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -219 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -36% Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -15%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -15%, Rev Chg QQuarterly Revenue Change % is -19% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -31% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -29% Key risksOPK key risks include [1] a history of operating losses and uncertain profitability, Show more. |
| Low stock price volatilityVol 12M is 37% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -87% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 10.91 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -219 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -36% |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is -15%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -15%, Rev Chg QQuarterly Revenue Change % is -19% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -31% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -29% |
| Key risksOPK key risks include [1] a history of operating losses and uncertain profitability, Show more. |
Qualitative Assessment
AI Analysis | Feedback
OPKO Health (OPK) stock has lost about 10% since 12/31/2025 because of the following key factors:
1. OPKO Health experienced a substantial decline in its consolidated total revenues in the fourth quarter of 2025, which were reported as $148.5 million, a decrease of 19.1% compared to $183.6 million in the same period of 2024. This reduction was primarily attributed to the sale of certain BioReference assets in 2025 and lower clinical test reimbursement rates.
2. The company shifted from a net income to a significant net loss in Q4 2025. OPKO Health reported a net loss of $31.3 million, or $0.04 per share, in the fourth quarter of 2025, contrasting with a net income of $14.0 million, or $0.01 per diluted share, in the fourth quarter of 2024. Concurrently, the operating loss for Q4 2025 increased to $38.3 million from $33.1 million in the comparable prior-year quarter.
Show more
1. OPKO Health experienced a substantial decline in its consolidated total revenues in the fourth quarter of 2025, which were reported as $148.5 million, a decrease of 19.1% compared to $183.6 million in the same period of 2024. This reduction was primarily attributed to the sale of certain BioReference assets in 2025 and lower clinical test reimbursement rates.
2. The company shifted from a net income to a significant net loss in Q4 2025. OPKO Health reported a net loss of $31.3 million, or $0.04 per share, in the fourth quarter of 2025, contrasting with a net income of $14.0 million, or $0.01 per diluted share, in the fourth quarter of 2024. Concurrently, the operating loss for Q4 2025 increased to $38.3 million from $33.1 million in the comparable prior-year quarter.
Show more
Stock Movement Drivers
Fundamental Drivers
The -7.9% change in OPK stock from 12/31/2025 to 4/11/2026 was primarily driven by a -5.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.26 | 1.16 | -7.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 642 | 607 | -5.5% |
| P/S Multiple | 1.5 | 1.5 | -4.0% |
| Shares Outstanding (Mil) | 777 | 766 | 1.4% |
| Cumulative Contribution | -7.9% |
Market Drivers
12/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| OPK | -7.9% | |
| Market (SPY) | -5.4% | 44.8% |
| Sector (XLV) | -4.8% | 43.3% |
Fundamental Drivers
The -25.2% change in OPK stock from 9/30/2025 to 4/11/2026 was primarily driven by a -20.4% change in the company's P/S Multiple.| (LTM values as of) | 9302025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.55 | 1.16 | -25.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 664 | 607 | -8.6% |
| P/S Multiple | 1.8 | 1.5 | -20.4% |
| Shares Outstanding (Mil) | 788 | 766 | 2.9% |
| Cumulative Contribution | -25.2% |
Market Drivers
9/30/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| OPK | -25.2% | |
| Market (SPY) | -2.9% | 30.3% |
| Sector (XLV) | 6.3% | 36.3% |
Fundamental Drivers
The -30.1% change in OPK stock from 3/31/2025 to 4/11/2026 was primarily driven by a -14.9% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312025 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.66 | 1.16 | -30.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 713 | 607 | -14.9% |
| P/S Multiple | 1.6 | 1.5 | -7.1% |
| Shares Outstanding (Mil) | 677 | 766 | -11.6% |
| Cumulative Contribution | -30.1% |
Market Drivers
3/31/2025 to 4/11/2026| Return | Correlation | |
|---|---|---|
| OPK | -30.1% | |
| Market (SPY) | 16.3% | 40.3% |
| Sector (XLV) | 2.3% | 41.8% |
Fundamental Drivers
The -20.5% change in OPK stock from 3/31/2023 to 4/11/2026 was primarily driven by a -39.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 3312023 | 4112026 | Change |
|---|---|---|---|
| Stock Price ($) | 1.46 | 1.16 | -20.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,004 | 607 | -39.6% |
| P/S Multiple | 1.1 | 1.5 | 34.0% |
| Shares Outstanding (Mil) | 752 | 766 | -1.9% |
| Cumulative Contribution | -20.5% |
Market Drivers
3/31/2023 to 4/11/2026| Return | Correlation | |
|---|---|---|
| OPK | -20.5% | |
| Market (SPY) | 63.3% | 27.0% |
| Sector (XLV) | 19.1% | 23.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OPK Return | 22% | -74% | 21% | -3% | -14% | -7% | -70% |
| Peers Return | 14% | -15% | -7% | -18% | 33% | -25% | -27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| OPK Win Rate | 50% | 25% | 50% | 58% | 33% | 25% | |
| Peers Win Rate | 60% | 50% | 50% | 44% | 43% | 40% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OPK Max Drawdown | -16% | -78% | -15% | -43% | -19% | -13% | |
| Peers Max Drawdown | -17% | -38% | -37% | -28% | -18% | -36% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: A, ATEC, CERS, POAS, TMO. See OPK Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)
How Low Can It Go
| Event | OPK | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -82.5% | -25.4% |
| % Gain to Breakeven | 470.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -50.4% | -33.9% |
| % Gain to Breakeven | 101.7% | 51.3% |
| Time to Breakeven | 32 days | 148 days |
| 2018 Correction | ||
| % Loss | -84.9% | -19.8% |
| % Gain to Breakeven | 560.6% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -88.8% | -56.8% |
| % Gain to Breakeven | 791.7% | 131.3% |
| Time to Breakeven | 951 days | 1,480 days |
Compare to A, ATEC, CERS, POAS, TMO
In The Past
OPKO Health's stock fell -82.5% during the 2022 Inflation Shock from a high on 2/1/2021. A -82.5% loss requires a 470.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About OPKO Health (OPK)
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. The company also offers specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, it operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
AI Analysis | Feedback
Like a smaller **Roche** that blends a major diagnostics business with a pharmaceutical division.
Think of it as if **Quest Diagnostics** also operated a significant biotech pipeline and commercialized its own medicines.
AI Analysis | Feedback
- BioReference Laboratories Services: Comprehensive laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of various diseases.
- 4Kscore Prostate Cancer Test: A specialized diagnostic test used for prostate cancer assessment.
- Rayaldee: A pharmaceutical product used to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
- hGH-CTP (Somatrogon): A once-weekly human growth hormone injection that completed Phase III clinical trials in partnership with Pfizer.
- OPK88003: A once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity, currently in Phase IIb trials.
- OPK88004: An orally administered selective androgen receptor modulator in development.
- Pharmaceutical Manufacturing and Distribution: Development, manufacture, marketing, and sale of various pharmaceutical, nutraceutical, veterinary, and ophthalmic products, including generics and specialty APIs.
- Point-of-Care Diagnostic System: A novel instrument system designed to provide rapid blood test results in a point-of-care setting.
AI Analysis | Feedback
OPKO Health (OPK) primarily sells its products and services to other companies and organizations, rather than directly to individual consumers. Based on the provided background information, its major customer categories include:
- Healthcare Providers: This encompasses physician offices, clinics, and hospitals that utilize its BioReference Laboratories for diagnostic testing services, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare. These entities also purchase its novel diagnostic instrument systems and pharmaceutical products.
- Pharmaceutical Distributors and Pharmacies: For its pharmaceutical products such as Rayaldee, as well as its generics, food supplements, and over-the-counter (OTC) products, OPKO primarily sells through pharmaceutical distributors and directly to pharmacy chains.
- Governmental Units and Employers: These organizations contract with BioReference Laboratories for diagnostic services, including correctional healthcare and potentially employee health screenings.
AI Analysis | Feedback
nullAI Analysis | Feedback
Phillip Frost, Chief Executive Officer and Chairman
Dr. Frost has served as the CEO and Chairman of OPKO Health, Inc. since March 2007. He previously held the positions of Chairman and Vice Chairman at Teva Pharmaceuticals Industries, Limited. From 1987 until its acquisition by Teva in January 2006, Dr. Frost was the Chairman of the Board and CEO of IVAX Corporation. He also served as Chairman for Key Pharmaceuticals from 1972 until its acquisition by Schering-Plough in 1986, which he bought with Michael Jaharis and sold for $836 million. Dr. Frost founded IVAX in 1987, a generic drug-making company, which he later sold to Teva Pharmaceuticals for $7.4 billion in 1995. He is also a Director of Cocrystal Pharma, Inc.
Adam Logal, Senior Vice President, Chief Financial Officer, Chief Accounting Officer, and Treasurer
Mr. Logal has served as OPKO's Senior Vice President and Chief Financial Officer since March 2014, and has held various finance roles at OPKO since March 2007. Before joining OPKO, he was in senior management at Nabi Biopharmaceuticals, a publicly traded biopharmaceutical company, from 2002 to 2007. Mr. Logal also served as President of GeneDx, an OPKO subsidiary, from July 2020 to June 2021. He currently chairs the board of directors of Xenetic Biosciences, Inc.
Steven D. Rubin, Executive Vice President, Administration and Director
Mr. Rubin has been the Executive Vice President, Administration at OPKO since May 2007 and a director since February 2007. He previously served as the Senior Vice President, General Counsel and Secretary of IVAX Corporation from August 2001 until September 2006. Mr. Rubin currently serves on the board of directors for several companies including Eloxx Pharmaceuticals, Inc., Cocrystal Pharma, Inc., Neovasc, Inc., Red Violet, Inc., and ChromaDex Corp.
Jane Hsiao, Chief Technical Officer and Vice Chairman
Dr. Hsiao holds the titles of Chief Technical Officer and Vice Chairman of the Board at OPKO Health. Her background is in pharmaceutical chemistry, and she possesses extensive technical expertise and senior management experience. She previously served as an Interim Chief Executive Officer of Non-Invasive Monitoring Systems Inc. Dr. Hsiao also serves as a director and/or chairman for other companies in the biotechnology and life sciences industry.
Elias A. Zerhouni M.D., President
Dr. Zerhouni is the President of OPKO Health. He is also the Chairman and co-founder of ModeX Therapeutics Inc., a wholly-owned subsidiary of OPKO. A physician-scientist specializing in Imaging and Biomedical Engineering, Dr. Zerhouni served as President of Global R&D and Executive Vice President of Sanofi from 2010 to 2018.
AI Analysis | Feedback
Key Risks to OPKO Health (OPK)
- Clinical Trial and Regulatory Approval Failures for Pipeline Products: OPKO Health has several key pharmaceutical products in its pipeline, including hGH-CTP (a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc.) and OPK88003 (a once-weekly peptide for type 2 diabetes and obesity in Phase IIb trials). The failure of these or other pipeline products to achieve successful clinical trial outcomes or obtain regulatory approval from health authorities would significantly impact the company's future revenue and growth prospects.
- Intense Competition and Reimbursement Pressures: The company's Diagnostics segment, primarily BioReference Laboratories, operates in a highly competitive market for laboratory testing services, facing ongoing pressure on pricing and reimbursement rates from governmental and private payers. Similarly, its Pharmaceutical segment, including products like Rayaldee and those in the generics market, faces competition from other pharmaceutical companies and potential pricing pressures.
- Intellectual Property Protection and Market Acceptance of Proprietary Versions: OPKO Health develops and commercializes "longer-acting proprietary versions of already approved therapeutic proteins." This strategy inherently carries risks related to securing, maintaining, and defending intellectual property rights against challenges. Additionally, the success of these proprietary versions depends on demonstrating sufficient clinical advantages and achieving market acceptance against existing treatments, including approved versions and potential biosimilars or generics.
AI Analysis | Feedback
The dominance of highly effective, already-approved GLP-1 receptor agonists in the treatment of type 2 diabetes and obesity presents a significant competitive barrier for OPKO's pipeline drug, OPK88003, which is currently in Phase IIb trials targeting the same indications.AI Analysis | Feedback
OPKO Health (OPK) operates in diverse diagnostics and pharmaceuticals markets, with several key products and services addressing significant addressable markets globally and within the United States.
Diagnostics Segment
- Clinical Reference Laboratory Services (BioReference Laboratories): The global clinical reference laboratory market was valued at approximately USD 45.6 billion in 2023 and is estimated to grow to USD 78 billion by 2032. In North America, this market was valued at USD 17.57 billion in 2023 and is projected to reach USD 29.10 billion by 2031.
- Anatomic Pathology (part of BioReference Laboratories): The U.S. anatomic pathology market was an estimated USD 37.1 billion in 2025.
- 4Kscore Prostate Cancer Testing Services: The global prostate cancer diagnostics market was valued at USD 8.57 billion in 2023 and is projected to reach USD 15.09 billion by 2032. North America held the largest share of the global prostate cancer biomarkers market, at 42.5% in 2024. Another estimate for the global prostate cancer diagnostics market size was USD 9.72 billion in 2025, anticipated to grow to approximately USD 18 billion by 2035.
Pharmaceuticals Segment
- Rayaldee (secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and vitamin D insufficiency): OPKO Health has previously indicated that Rayaldee's addressable market is valued at USD 12 billion. The U.S. secondary hyperparathyroidism (SHPT) treatment market was valued at USD 6.51 billion in 2024 and is projected to reach USD 11.77 billion by 2033. The global secondary hyperparathyroidism treatment market was valued at USD 1.12 billion in 2023 and is projected to grow with a CAGR of 9.62% through 2029. North America dominates the global secondary hyperparathyroidism treatment market. The global vitamin D market, which is related to vitamin D insufficiency, was valued at USD 1.35 billion in 2025 and is estimated to grow to USD 2.47 billion by 2034.
- OPK88003 (treatment for type 2 diabetes and associated obesity): The global type 2 diabetes market size was USD 48.14 billion in 2024 and is expected to reach USD 51.96 billion in 2025, with projections to grow to USD 72.22 billion by 2029. North America was the largest regional market for type 2 diabetes in 2024. The global obesity treatment market was valued at USD 15.92 billion in 2024 and is projected to reach USD 60.53 billion by 2030. The obesity market in the seven major markets (France, Germany, Italy, Japan, Spain, the UK, and the US) is estimated to exceed USD 173.5 billion by 2031. The U.S. alone represents approximately 80% of the obesity market size within these seven major markets.
- hGH-CTP (once-weekly human growth hormone injection): The global human growth hormone market generated USD 6,321.8 million in revenue in 2023 and is expected to reach USD 14,279.5 million by 2030. The U.S. human growth hormone market size was valued at USD 2.47 billion in 2024 and is expected to reach approximately USD 7.94 billion by 2034. North America was the largest revenue-generating market for human growth hormone in 2023 and 2024.
AI Analysis | Feedback
The expected drivers of future revenue growth for OPKO Health (OPK) over the next 2-3 years include:- Global Commercialization of NGENLA (Somatrogon) through the Pfizer Partnership: OPKO Health anticipates continued revenue growth from its long-acting growth hormone, NGENLA (somatrogon), which is being commercialized globally in partnership with Pfizer. Following its approvals in the E.U. and Japan in 2023, this initiative targets a potential $1.5 billion global market. The company has already seen a significant increase in royalties from NGENLA, with a 45% year-over-year surge in 2024, reaching $145 million. Gross profit share payments from Pfizer for NGENLA also increased in the fourth quarter of 2025, reflecting its global commercial progress.
- Expansion and Increased Adoption of the 4Kscore Test: OPKO Health's Diagnostics segment is expected to see growth driven by its 4Kscore prostate cancer test. The test has demonstrated increased demand and higher average reimbursement, contributing to a 16% revenue increase in the fourth quarter of 2025 compared to the prior year. Management projects 4Kscore growth at a high single-digit to low double-digit pace into 2026, supported by an FDA label change that removes the requirement for a digital rectal exam (DRE) and expansion into the urology market.
- Advancement and Monetization of the ModeX Therapeutics Pipeline through Strategic Collaborations: The acquisition of ModeX Therapeutics in 2023 significantly accelerated OPKO's pipeline in high-value oncology and immunology therapeutics. Collaborations, such as the research partnership with Regeneron Pharmaceuticals for multispecific antibodies, are expected to generate substantial potential milestone payments exceeding $200 million for each program and tiered royalties on global net sales, with Regeneron funding preclinical and clinical development as well as commercialization activities. Additionally, the progress of other pipeline candidates, including the Merck-partnered Epstein-Barr virus (EBV) vaccine (Phase 1 completed in Q4 2025) and MDX2003 for leukemia and lymphoma (Phase 1 studies expected to begin in H1 2026), are anticipated to contribute to future revenue.
- Growth in International Pharmaceutical Sales and Sustained Performance of Rayaldee: OPKO's Pharmaceutical segment is expected to benefit from higher sales volumes in its international operations, which contributed to an increase in pharmaceutical product sales in the fourth quarter of 2025. While Rayaldee sales have experienced some fluctuations, the product remains a flagship renal therapy, and management has noted improved profit margins in 2025 due to lower government rebate expenses. Rayaldee's continued sales momentum is supported by effective sales efforts and broad distribution channels.
AI Analysis | Feedback
Share Repurchases
- OPKO Health authorized a $200 million common stock repurchase program in April 2025, increasing it by $100 million from an existing program authorized in July 2024.
- The company repurchased approximately $87.3 million of common stock under this program since its authorization in July 2024, as of December 31, 2025.
- As of December 31, 2025, approximately $112.7 million remained authorized and available for future repurchases under the program.
Share Issuance
- In April 2025, OPKO Health issued 121 million shares of common stock and paid approximately $65 million in cash to extinguish over $159 million of outstanding convertible notes.
Outbound Investments
- OPKO Health completed the sale of BioReference Health's oncology and related clinical assets to Labcorp for $225 million in September 2025, including $192.5 million paid at closing and up to $32.5 million in performance-based earnouts.
- In the third quarter of 2025, the company entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies, with potential milestone payments exceeding $1 billion plus tiered royalties for its ModeX subsidiary. Regeneron is responsible for funding development and commercialization.
- In February 2025, OPKO Health expanded its collaboration with Entera Bio Ltd. to develop an oral long-acting PTH analog, with both companies holding a 50% ownership interest and sharing development costs for the program.
Capital Expenditures
- OPKO Health reported capital expenditures of $11 million in 2025, $17 million in 2024, $39 million in 2023, $27 million in 2022, and $12 million in 2021.
- The primary focus of capital expenditures includes investments in software, machinery, medical and other equipment, furniture and fixtures, and leasehold improvements.
- Research and development (R&D) spending, a key capital allocation for future product development, was guided to be $120 million–$130 million for 2025.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| OPKO Health Earnings Notes | 12/16/2025 | |
| With OPKO Health Stock Sliding, Have You Assessed The Risk? | 10/17/2025 | |
| OPKO Health (OPK) Operating Cash Flow Comparison | 08/08/2025 | |
| OPKO Health (OPK) Debt Comparison | 08/08/2025 | |
| OPKO Health (OPK) Net Income Comparison | 08/08/2025 | |
| OPKO Health (OPK) EBITDA Comparison | 08/08/2025 | |
| OPKO Health (OPK) Tax Expense Comparison | 08/08/2025 | |
| OPKO Health (OPK) Revenue Comparison | 08/08/2025 | |
| OPKO Health (OPK) Operating Income Comparison | 08/08/2025 | |
| OPK Dip Buy Analysis | 07/10/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to OPK.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 03312026 | PGNY | Progyny | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 03272026 | CNC | Centene | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 2.3% | 2.3% | -0.6% |
| 03272026 | OSCR | Oscar Health | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 3.0% | 3.0% | -2.6% |
| 03202026 | WAT | Waters | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -0.4% | -0.4% | -3.3% |
| 03202026 | GILD | Gilead Sciences | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 1.6% | 1.6% | -2.2% |
| 05312022 | OPK | OPKO Health | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | -53.0% | -53.7% | -65.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 6.40 |
| Mkt Cap | 1.7 |
| Rev LTM | 764 |
| Op Inc LTM | -9 |
| FCF LTM | 1 |
| FCF 3Y Avg | -13 |
| CFO LTM | 45 |
| CFO 3Y Avg | -9 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.1% |
| Rev Chg 3Y Avg | 0.8% |
| Rev Chg Q | 7.2% |
| QoQ Delta Rev Chg LTM | 1.9% |
| Op Mgn LTM | -4.2% |
| Op Mgn 3Y Avg | -9.6% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 5.9% |
| CFO/Rev 3Y Avg | -5.9% |
| FCF/Rev LTM | 0.5% |
| FCF/Rev 3Y Avg | -8.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.7 |
| P/S | 2.2 |
| P/EBIT | -6.7 |
| P/E | -3.9 |
| P/CFO | 23.7 |
| Total Yield | -4.3% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -3.0% |
| D/E | 0.3 |
| Net D/E | 0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 3.8% |
| 3M Rtn | -21.1% |
| 6M Rtn | -16.2% |
| 12M Rtn | 12.4% |
| 3Y Rtn | -25.3% |
| 1M Excs Rtn | -0.6% |
| 3M Excs Rtn | -18.0% |
| 6M Excs Rtn | -21.0% |
| 12M Excs Rtn | -20.6% |
| 3Y Excs Rtn | -92.3% |
Price Behavior
Price Behavior
| Market Price | $1.16 | |
| Market Cap ($ Bil) | 0.9 | |
| First Trading Date | 11/02/1995 | |
| Distance from 52W High | -26.6% | |
| 50 Days | 200 Days | |
| DMA Price | $1.19 | $1.33 |
| DMA Trend | down | down |
| Distance from DMA | -2.6% | -12.6% |
| 3M | 1YR | |
| Volatility | 36.0% | 36.4% |
| Downside Capture | 0.76 | 0.78 |
| Upside Capture | 104.08 | 85.65 |
| Correlation (SPY) | 41.0% | 39.6% |
OPK Betas & Captures as of 3/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.50 | 1.33 | 1.25 | 0.81 | 0.80 | 0.93 |
| Up Beta | -0.85 | 0.03 | 1.96 | 0.84 | 0.44 | 0.78 |
| Down Beta | 0.34 | 1.31 | 1.06 | 0.80 | 0.93 | 0.88 |
| Up Capture | 337% | 177% | 117% | 46% | 67% | 81% |
| Bmk +ve Days | 7 | 16 | 27 | 65 | 139 | 424 |
| Stock +ve Days | 8 | 14 | 23 | 47 | 92 | 303 |
| Down Capture | 154% | 141% | 123% | 105% | 122% | 105% |
| Bmk -ve Days | 12 | 23 | 33 | 58 | 110 | 323 |
| Stock -ve Days | 10 | 20 | 31 | 61 | 118 | 353 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPK | |
|---|---|---|---|---|
| OPK | -20.6% | 37.6% | -0.54 | - |
| Sector ETF (XLV) | 12.3% | 16.8% | 0.52 | 42.6% |
| Equity (SPY) | 31.2% | 17.3% | 1.47 | 39.2% |
| Gold (GLD) | 60.1% | 27.8% | 1.69 | 2.5% |
| Commodities (DBC) | 29.8% | 16.6% | 1.58 | 10.4% |
| Real Estate (VNQ) | 21.3% | 15.2% | 1.07 | 31.4% |
| Bitcoin (BTCUSD) | -4.3% | 43.7% | 0.02 | 22.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPK | |
|---|---|---|---|---|
| OPK | -23.9% | 56.5% | -0.25 | - |
| Sector ETF (XLV) | 6.3% | 14.6% | 0.25 | 32.5% |
| Equity (SPY) | 11.1% | 17.0% | 0.50 | 37.3% |
| Gold (GLD) | 22.1% | 17.8% | 1.02 | 5.3% |
| Commodities (DBC) | 11.8% | 18.8% | 0.52 | 6.3% |
| Real Estate (VNQ) | 3.7% | 18.8% | 0.10 | 33.5% |
| Bitcoin (BTCUSD) | 4.3% | 56.5% | 0.30 | 20.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OPK | |
|---|---|---|---|---|
| OPK | -19.7% | 64.6% | -0.06 | - |
| Sector ETF (XLV) | 9.8% | 16.5% | 0.48 | 32.3% |
| Equity (SPY) | 13.8% | 17.9% | 0.66 | 33.1% |
| Gold (GLD) | 14.2% | 15.9% | 0.74 | 5.7% |
| Commodities (DBC) | 8.6% | 17.6% | 0.41 | 9.8% |
| Real Estate (VNQ) | 5.1% | 20.7% | 0.22 | 25.5% |
| Bitcoin (BTCUSD) | 67.6% | 66.9% | 1.07 | 11.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/26/2026 | 0.0% | -2.5% | -6.7% |
| 10/29/2025 | 2.1% | -6.3% | -7.7% |
| 7/31/2025 | -7.0% | -3.9% | 7.8% |
| 2/27/2025 | 6.7% | 16.0% | 4.3% |
| 11/7/2024 | 4.8% | 11.7% | 9.0% |
| 8/7/2024 | 11.7% | 19.5% | 21.9% |
| 5/7/2024 | -3.8% | 0.4% | 3.1% |
| 2/27/2024 | -6.1% | -11.0% | 1.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 10 | 14 |
| # Negative | 11 | 11 | 7 |
| Median Positive | 4.4% | 11.4% | 8.8% |
| Median Negative | -7.0% | -4.5% | -9.5% |
| Max Positive | 20.1% | 21.7% | 21.9% |
| Max Negative | -16.7% | -17.5% | -37.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/26/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/31/2025 | 10-Q |
| 03/31/2025 | 05/01/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 03/01/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/03/2023 | 10-Q |
| 03/31/2023 | 05/03/2023 | 10-Q |
| 12/31/2022 | 02/27/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q1 2026 Total revenues | 125.00 Mil | 132.50 Mil | 140.00 Mil | ||||
| Q1 2026 Services revenue | 71.00 Mil | 73.00 Mil | 75.00 Mil | ||||
| Q1 2026 Product revenue | 38.00 Mil | 41.50 Mil | 45.00 Mil | ||||
| Q1 2026 IP and other revenue | 15.00 Mil | 17.50 Mil | 20.00 Mil | ||||
| Q1 2026 Total costs and expenses | 170.00 Mil | 175.00 Mil | 180.00 Mil | ||||
| Q1 2026 R&D included in costs and expenses | 30.00 Mil | 31.00 Mil | 32.00 Mil | ||||
| 2026 Total revenues | 530.00 Mil | 545.00 Mil | 560.00 Mil | ||||
| 2026 Services revenue | 300.00 Mil | 306.00 Mil | 312.00 Mil | ||||
| 2026 Product revenue | 160.00 Mil | 165.00 Mil | 170.00 Mil | ||||
| 2026 IP and other revenue | 70.00 Mil | 75.00 Mil | 80.00 Mil | ||||
| 2026 Total costs and expenses | 725.00 Mil | 737.50 Mil | 750.00 Mil | ||||
| 2026 R&D included in costs and expenses | 125.00 Mil | 130.00 Mil | 135.00 Mil | ||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Frost, Phillip Md Et Al | CEO & Chairman | See Footnote | Buy | 11212025 | 1.33 | 580,000 | 768,807 | 287,250,900 | Form |
| 2 | Frost, Phillip Md Et Al | CEO & Chairman | See Footnote | Buy | 11202025 | 1.33 | 580,000 | 771,328 | 287,421,235 | Form |
| 3 | Frost, Phillip Md Et Al | CEO & Chairman | See Footnote | Buy | 11192025 | 1.31 | 580,000 | 759,115 | 282,111,430 | Form |
| 4 | Frost, Phillip Md Et Al | CEO & Chairman | See Footnote | Buy | 11182025 | 1.27 | 533,300 | 678,906 | 273,658,307 | Form |
| 5 | Frost, Phillip Md Et Al | CEO & Chairman | See Footnote | Buy | 10312025 | 1.42 | 150,000 | 213,435 | 305,050,477 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.